An equine bone marrow aspirate concentrate protocol yields a predictable cellular and cytokine profile
Equine Veterinary Journal · 15.11.2026
DOI: 10.1002/evj.70353 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Equine Veterinary Journal, online erschienen am 15.11.2026. Verfasst von Megan Branning und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Bone marrow aspirate concentrate (BMAC) is a quick, minimally invasive, point‐of‐care therapy for equine orthopaedic injuries. Despite growing clinical use, standardised manufacturing methods are lacking, and the final product remains poorly characterised.
Objective
To develop a reproducible protocol for equine BMAC production that yields predictable cellular and cytokine compositions. Study Design In vitro analytical study.
Methods
Bone marrow aspirate (BMA) was harvested from the sternum of eight healthy adult horses and filtered to remove possible bony spicules. After centrifugation at 1000 × g for 10 min, the buffy coat was collected to generate BMAC. Cellular composition was assessed using standard haematology and cytology, and cytokine concentrations were measured using commercially available enzyme‐linked immunosorbent assay (ELISA) kits. Data are presented as mean ± standard deviation.
Results
BMA filtration successfully removed potential bony material without significantly altering the cellular profile. Cells were predictably concentrated in BMAC: total nucleated cells increased from 77 ± 30 × 10 3 /μL to 240 ± 57 × 10 3 /μL; and platelets from 119 ± 34 × 10 3 /μL to 269 ± 81 × 10 3 /μL. Anti‐inflammatory cytokines were increased in BMAC: IL‐1ra increased from 18,611.3 ± 5509.1 to 36,598.8 ± 5971.8 pg/mL; IL‐10 from 9.0 ± 7.5 to 19.1 ± 15.6 ng/mL; and TGF‐β1 from 2535.0 ± 3018.7 to 5073.8 ± 2175.9 pg/mL. Of the pro‐inflammatory cytokines measured, only IL‐1β was increased (287.5 ± 22.5 to 475.1 ± 206.0 pg/mL), while TNF‐α and IL‐6 were unchanged. Main Limitations The small cohort size ( n = 8) limited sensitivity for detecting minor effects. The cytokine panel, while representative, does not encompass all potential bioactive mediators, and single‐time‐point measurements do not necessarily reflect in vivo release kinetics. The clinical efficacy of BMAC was not evaluated, preventing direct correlation between compositional features and therapeutic outcomes.
Conclusions
The BMAC protocol yielded consistently concentrated nucleated cells, preserved cellular morphology, and enhanced the anti‐inflammatory cytokine profile relative to post‐filtration BMA. These findings provide a biological rationale for intra‐articular and intra‐lesional use of BMAC in equine patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
ORCID-Profile: Julie Gordon, Samantha N Schlemmer, John F Peroni
Zitieren
APA
Branning, M., Gordon, J., Schlemmer, S. N., & Peroni, J. F. (2026). An equine bone marrow aspirate concentrate protocol yields a predictable cellular and cytokine profile. Equine Veterinary Journal. https://doi.org/10.1002/evj.70353
Vancouver
Branning M, Gordon J, Schlemmer SN, Peroni JF. An equine bone marrow aspirate concentrate protocol yields a predictable cellular and cytokine profile. Equine Veterinary Journal. 2026. doi:10.1002/evj.70353
BibTeX
@article{Branning2026,
author = {Branning, Megan and Gordon, Julie and Schlemmer, Samantha N and Peroni, John F},
title = {An equine bone marrow aspirate concentrate protocol yields a predictable cellular and cytokine profile},
journal = {Equine Veterinary Journal},
year = {2026},
doi = {10.1002/evj.70353}
}
EUVIMED